Drug Addiction – Pipeline Review, H1 2018

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction – Pipeline Review, H1 2018, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 8, 1, 29, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 14 and 6 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).

– The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Addex Therapeutics Ltd

Aelis Farma SAS

Aphios Corp

BioCorRx Inc

Charleston Laboratories Inc

Chiesi Farmaceutici SpA

Consegna Pharma Inc

Curemark LLC

Egalet Corp

Embera NeuroTherapeutics Inc

F. Hoffmann-La Roche Ltd

Heptares Therapeutics Ltd

Immunovaccine Inc

InterveXion Therapeutics LLC

Intra-Cellular Therapies Inc

Johnson & Johnson

Kyorin Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Omeros Corp

Orexigen Therapeutics Inc

P2D Bioscience

Saniona AB

Stada Arzneimittel AG

Teva Pharmaceutical Industries Ltd

Vectura Group Plc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Drug Addiction - Overview 6

Drug Addiction - Therapeutics Development 7

Drug Addiction - Therapeutics Assessment 18

Drug Addiction - Companies Involved in Therapeutics Development 28

Drug Addiction - Drug Profiles 40

Drug Addiction - Dormant Projects 143

Drug Addiction - Discontinued Products 146

Drug Addiction - Product Development Milestones 147

Appendix 156

List of Tables

List of Tables

Number of Products under Development for Drug Addiction, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Drug Addiction – Pipeline by Addex Therapeutics Ltd, H1 2018

Drug Addiction – Pipeline by Aelis Farma SAS, H1 2018

Drug Addiction – Pipeline by Aphios Corp, H1 2018

Drug Addiction – Pipeline by BioCorRx Inc, H1 2018

Drug Addiction – Pipeline by Charleston Laboratories Inc, H1 2018

Drug Addiction – Pipeline by Chiesi Farmaceutici SpA, H1 2018

Drug Addiction – Pipeline by Consegna Pharma Inc, H1 2018

Drug Addiction – Pipeline by Curemark LLC, H1 2018

Drug Addiction – Pipeline by Egalet Corp, H1 2018

Drug Addiction – Pipeline by Embera NeuroTherapeutics Inc, H1 2018

Drug Addiction – Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Drug Addiction – Pipeline by Heptares Therapeutics Ltd, H1 2018

Drug Addiction – Pipeline by Immunovaccine Inc, H1 2018

Drug Addiction – Pipeline by InterveXion Therapeutics LLC, H1 2018

Drug Addiction – Pipeline by Intra-Cellular Therapies Inc, H1 2018

Drug Addiction – Pipeline by Johnson & Johnson, H1 2018

Drug Addiction – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Drug Addiction – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Drug Addiction – Pipeline by Omeros Corp, H1 2018

Drug Addiction – Pipeline by Orexigen Therapeutics Inc, H1 2018

Drug Addiction – Pipeline by P2D Bioscience, H1 2018

Drug Addiction – Pipeline by Saniona AB, H1 2018

Drug Addiction – Pipeline by Stada Arzneimittel AG, H1 2018

Drug Addiction – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018

Drug Addiction – Pipeline by Vectura Group Plc, H1 2018

Drug Addiction – Dormant Projects, H1 2018

Drug Addiction – Dormant Projects, H1 2018 (Contd..1), H1 2018

Drug Addiction – Dormant Projects, H1 2018 (Contd..2), H1 2018

Drug Addiction – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Drug Addiction, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports